Founder & CEO, Baywind Bioventures
SubQ Biologics™: Innovative Nano/Microparticle Injectable Technology
SubQ Biologics is a patented nano/micro-particle formulation for salts of biologics composed of GRAS excipients. The particulate technology is designed to modulate the solubility and dissolution properties of the biologics in physiological buffer at pH 7.4.
The particulate formulations can be used to create extended-release PK profiles, to improve bioavailability of subcutaneous injection, to mitigate injection site reactions, and to create high concentration particulate suspensions for high dose proteins and antibodies.
The biologics particulates are produced via a simple aqueous particle precipitation process, under mild conditions (water or phosphate buffered saline) and are isolated in high yields (>80%). Active content ranges from 30% to over 80% depending on the properties of the particulate form desired. Stability of the particulates should allow for long term storage at 5C and potentially higher, depending on the biologic.
Chris Rhodes, Ph.D. founded Baywind Bioventures is an incubator of novel drug delivery platforms. Chris has over 24 years of consulting and executive leadership roles in pharmaceutical, biotechnology, and drug delivery companies. He has extensive experience translating molecular therapeutics, formulation, delivery, and device programs from late stage research into clinical development.